Document is current

Any future updates will be listed below

Immunogenicity and safety of a recombinant gE-Fc fusion protein subunit vaccine for herpes zoster in adults ≥50 years of age: a randomised, active-controlled, non-inferiority trial

Crossref DOI link: https://doi.org/10.1038/s41467-025-62800-z

Published Online: 2025-08-15

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark